Kintara Therapeutics, Inc. (KTRA) |
|
7.08 0.52 (7.93%)
|
02-02 15:59 |
|
Open: |
6.65 |
Pre. Close: |
6.56 |
|
High:
|
7.2202 |
Low:
|
6.5 |
|
Volume:
|
13,458 |
Market Cap:
|
11(M) |
|
|
|
Technical analysis |
as of: 2023-02-02 3:43:17 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time. |
| Target: |
Six months: 8.99 One year: 10.51 |
| Support: |
Support1: 5.59 Support2: 4.65 |
| Resistance: |
Resistance1: 7.69 Resistance2: 9 |
| Pivot: |
6.53 |
| Moving Average: |
MA(5): 6.52  MA(20): 6.86
MA(100): 6.58 MA(250): 10.39 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 43.3 %D(3): 35.3 |
| RSI: |
RSI(14): 49.7 |
| 52-week: |
High: 42 Low: 0.18 |
| Average Vol(K): |
3-Month: 403 (K) 10-Days: 29 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KTRA ] has closed below upper band by 28.1%. Bollinger Bands are 50.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.65 - 6.67 |
6.67 - 6.7 |
|
Low:
|
6.35 - 6.38 |
6.38 - 6.41 |
|
Close:
|
6.51 - 6.55 |
6.55 - 6.6 |
|
Company Description |
|
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. |
Headline News |
Thu, 02 Feb 2023
Where Does Wall Street Think Kintara Therapeutics Inc (KTRA) Stock Will Go? - InvestorsObserver
Tue, 31 Jan 2023
Should You Buy Kintara Therapeutics Inc (KTRA) in Biotechnology ... - InvestorsObserver
Thu, 26 Jan 2023
Healthcare Stocks Moving Thursday: SCLX, KALA, KTRA, SNOA, OCUP, THMO, FNA, SHPH - InvestorsObserver
Tue, 10 Jan 2023
Kintara Therapeutics to Present at the Biotech Showcase ... - PR Newswire
Thu, 15 Dec 2022
Kintara Therapeutics Receives Orphan Drug Designation for VAL ... - PR Newswire
Tue, 29 Nov 2022
Should You Buy Kintara Therapeutics Inc (KTRA) Stock on Tuesday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
49 (M) |
| Shares Float |
79 (M) |
|
% Held by Insiders
|
6.3 (%) |
|
% Held by Institutions
|
4.6 (%) |
|
Shares Short
|
688 (K) |
|
Shares Short P.Month
|
809 (K) |
Stock Financials |
|
EPS
|
-0.9 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.12 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-96.2 |
|
Return on Equity (ttm)
|
-202.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.47 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-20 (M) |
|
Levered Free Cash Flow
|
-11 (M) |
Stock Valuations |
|
PE Ratio
|
-7.72 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
53.38 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-16.53 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-05-07 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
